ResearcherHomi Bhabha National InstituteActive in the last 2 years
Reena Z. Engineer
Matched on ORCID iD 0000-0002-3893-1287; OpenAlex author ID A5055804272. Sources: ClinicalTrials.gov.
Their work
- Papers
- 3
- Trials
- 1 (principal investigator on 1)
- Grants
- 0
- Labs led
- 0
- Collaborators
- 7
2008: 1 trial · 2009: none · 2010: none · 2011: none · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper
Papers 3
- Differential impact of incrementally elevated CA 19-9 levels on prognosis of resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2024.06.004↗
- Neoadjuvant therapy in borderline resectable pancreatic cancer: Outcomes in the era of changing practices and evolving evidence. Co-author DOI 10.1016/j.surg.2021.10.018↗
- Nontrial, real-world outcomes in unresectable locally advanced pancreatic cancer: Chemotherapy and chemoradiation is the standard while surgery is uncommon. Co-author DOI 10.4103/ijc.ijc_377_17↗
Trials 1
- Tomotherapy in Locally Advanced Gallbladder and Pancreatic Cancers Principal investigator NCT01118897↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Vikas S. Ostwal · 3 shared papers, 2017–2024 · strength 0.42
- Paper Differential impact of incrementally elevated CA 19-9 levels on prognosis of resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.hpb.2024.06.004↗
- Paper Neoadjuvant therapy in borderline resectable pancreatic cancer: Outcomes in the era of changing practices and evolving … DOI 10.1016/j.surg.2021.10.018↗
- Paper Nontrial, real-world outcomes in unresectable locally advanced pancreatic cancer: Chemotherapy and chemoradiation is th… DOI 10.4103/ijc.ijc_377_17↗
- Shailesh Vinayak Shrikhande · 3 shared papers, 2017–2024 · strength 0.42
- Paper Differential impact of incrementally elevated CA 19-9 levels on prognosis of resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.hpb.2024.06.004↗
- Paper Neoadjuvant therapy in borderline resectable pancreatic cancer: Outcomes in the era of changing practices and evolving … DOI 10.1016/j.surg.2021.10.018↗
- Paper Nontrial, real-world outcomes in unresectable locally advanced pancreatic cancer: Chemotherapy and chemoradiation is th… DOI 10.4103/ijc.ijc_377_17↗
- Anant Ramaswamy · 3 shared papers, 2017–2024 · strength 0.42
- Paper Differential impact of incrementally elevated CA 19-9 levels on prognosis of resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.hpb.2024.06.004↗
- Paper Neoadjuvant therapy in borderline resectable pancreatic cancer: Outcomes in the era of changing practices and evolving … DOI 10.1016/j.surg.2021.10.018↗
- Paper Nontrial, real-world outcomes in unresectable locally advanced pancreatic cancer: Chemotherapy and chemoradiation is th… DOI 10.4103/ijc.ijc_377_17↗
- Vikram Anil Chaudhari · 2 shared papers, 2022–2024 · strength 0.35
- Paper Differential impact of incrementally elevated CA 19-9 levels on prognosis of resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.hpb.2024.06.004↗
- Paper Neoadjuvant therapy in borderline resectable pancreatic cancer: Outcomes in the era of changing practices and evolving … DOI 10.1016/j.surg.2021.10.018↗
- Manish Suresh BHANDARE · 2 shared papers, 2022–2024 · strength 0.35
- Paper Differential impact of incrementally elevated CA 19-9 levels on prognosis of resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.hpb.2024.06.004↗
- Paper Neoadjuvant therapy in borderline resectable pancreatic cancer: Outcomes in the era of changing practices and evolving … DOI 10.1016/j.surg.2021.10.018↗
- Bhawna Sirohi · 1 shared paper, 2022 · strength 0.14
- Abhishek Mitra · 1 shared paper, 2022 · strength 0.14
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.